Skip to main content

Table 1 Description of the study populations

From: The data management of a phase III efficacy trial of an 11-valent pneumococcal conjugate vaccine and related satellite studies conducted in the Philippines

Study Study areas Age of population Study group
Phase 3 RCT study    
Efficacy study 6 study municipalities Children aged 6 weeks to 6 months and monitored until 2 years old RCT
Nested study 3 predefined health centres included Dao (Tagbilaran), Danao and main health centre in Panglao Children aged 6 weeks to 6 months and monitored until 2 years old RCT
Hospitalization in BRH 6 study municipalities Children less than 5 years old RCT, EPI and Epi grey
Hospitalization in the private hospital and OPD consultation in BRH 6 study municipalities Children less than 2 years old RCT, EPI and Epi grey
Satellite studies    
Herd immunity 6 study municipalities Children enrolled in the efficacy study w/elder sibling enrolled in the efficacy study RCT
Cost effectiveness(hospitalization for pneumonia, sepsis, or meningitis at BRH and three private hospitals) 6 study municipalities Children enrolled in the efficacy study from 6 weeks to 23 months old and admitted to hospital or consulted the OPD RCT
Acute otitis media(hospitalization or consultation at BRH for pneumonia, sepsis, or meningitis) 6 study municipalities Children less than 5 years old diagnosed with pneumonia and/or AOM RCT, EPI and Epi grey
Wheezing(hospitalization or consultation at BRH for pneumonia, sepsis, or meningitis) 6 study municipalities Children less than 5 years old RCT, EPI and Epi grey
Pertussis(hospitalization or consultation at BRH for pneumonia, sepsis, or meningitis) 6 study municipalities Children less than 13 years old RCT, EPI and Epi grey, children not necessary enrolled in RCT